Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

Hepatology

Volumn 25, Issue 4, 1997, Pages 991-994

  Rayyes, Osama A L ^a,b   Wallmark, Anders ^a   Florén, Claes Henrik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Malrno University Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPACTIN; CYCLOSPORIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LIPOPROTEIN METABOLISM; LIVER METABOLISM; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CYCLOSPORINE; DOWN-REGULATION; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; LIPOPROTEINS, LDL; LOVASTATIN; RECEPTORS, LDL; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 20644458773     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250433     Document Type: Article

References (26)

1. Gunnarsson R, Löfmark R, Nordlander R, Nyquist O, Groth C-G. Acute myocardial infarction in renal transplant recipients: incidence and prognosis. Eur Heart J 1984;5:218-221.
2. Uretsky BF, Murali S, Reddy PS, Rabbin B, Lee A, Griffith BP, Hardesty RL, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987;76:827-833.
3. Drüeke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 1991;39(suppl 31):24-28.
4. López-Miranda J, Pérez-Jiménez F, Torres A, Espino-Montoro A, Gomez P, Hidalgo-Rojas L, Ordovas MJ, et al. Effects of cyclosporine on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992; 25:379-386.
5. Stone JN. Secondary causes of hyperlipidaemia. Med Clin North Am 1994; 78:117-141.
6. Havel RJ, Hamilton RL. Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism. HEPATOLOGY 1988;8:1689-1704.
7. Avitt NB. HepG2 cells as a resource for metabolic studies: lipoproteins, cholesterol, and bile acids. FASEB J 1990;4:161-168.
8. Havekes L, Van Hinsbergh V, Kempen HL, Eneis J. The metabolism in vitro of human low-density lipoprotein by human hepatoma cell line HepG2. Biochem J 1983;214:951-958.
9. Al Rayyes O, Wallmark A, Floren C-H. Cyclosporine inhibits catabolism of low-density lipoproteins in Hep G2 cells by 25%. HEPATOLOGY 1996;24: 613-619.
10. Kandus A, Kovae D, Kveder R, Bren AF. Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression. Transplant Proc 1994;26:2642-2643.
11. Regazzi MB, Lacona I, Campana C, Gavazzi A, Vigano M, Perani G. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporine A. Transplant Proc 1994;26:2644-2645.
12. Vanhaecke J, Cleemput JV, Lierde JV, Daenen W, Geest HD. Safety and efficacy of low dose Simvastatin in cardiac transplant recipients treated with Cyclosporine. Transplantation 1994;58:42-45.
13. Arnadoittir M, Eriksson L-O, Germershausen JI, Thysell H. Low dose Simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in cyclosporine-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients. Nephron 1994;68:57-62.
14. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D-11D.
15. Walker JF. HMG CoA reductase inhibitors: current clinical experience. Drugs 1988;36(suppl 3):83-86.
16. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-1353.
17. Mc Farlane AS. Efficient trace-labelling of proteins with iodine [Abstract]. Nature 1958;182:53.
18. Bierman RL, Stein O, Stein Y. Lipoprotein uptake and metabolism by aortic smooth muscle cells in tissue culture. Circ Res 1974;35:136-150.
19. Salter AM, Saxton J, Brindley D. Characterization of the binding of human low-density lipoprotein to primary monolayer cultures of rat hepatocytes. Biochem J 1986;240:549-557.
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with folin phenol reagents. J Biol Chem 1951;193:265-275.
21. Afifi AA, Azen SP. Statistical Analysis. A Computer Oriented Approach. 2nd ed. New York: Academic, 1977.
22. Norusis MJ. SPSS for Windows, rel. 6.0. SPSS Inc., Chicago, IL, 1993.
23. Hayashi K, Kurokawa J, Normura S, Kuga Y, Ohkura Y, Kajiyama G. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Biochim Biophys Acta 1993;1167:223-225.
24. Liao W, Floren C-H. Upregulation of low density lipoprotein receptor activity by tumor necrosis factor, a process independent of tumor necrosis factor-induced lipid synthesis and secretion. Lipids 1994;29:679-684.
25. López-Miranda J, Vilella E, Pérez-Jiménez F, Espino A, Jiménez-Pere-pérez J A, Massana L, Turner PR. Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism 1993;42:678-683.
26. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB. Rhabdomyolysis and renal injury with Lovastatin use. JAMA 1988;260:239-241.